Elephas
Elephas is developing a platform that utilizes fresh biopsies to preserve the tumor microenvironment for evaluating immunotherapy response.
This enables drug developers to stratify trial patient populations and identify a drug’s true potential.
The Elephas Live™ platform will help inform patient selection in 72 hours using proprietary technology and unique sequential treatment strategy, which addresses tumor heterogeneity and helps predict cytokine response to immunotherapy.
Partner with us to revolutionize immunotherapy treatment and transform cancer care.
